阅读说明：本技术 一种仿生医用防粘连膜的制备方法 (Preparation method of bionic medical anti-adhesion membrane ) 是由 张洪程 何如忻 杜志云 于 2021-09-08 设计创作，主要内容包括：本发明提供了一种仿生医用防粘连膜的制备方法,包括将PMPC以及PCL于室温的条件下添加至溶剂中,搅拌制备纺丝液；将纺丝液装载至注射器内,使用铝箔为接收器,调节纺丝装置和接收器间距为16-20cm,施加电压为10-30kv,在第一环境条件下纺丝制备第一膜层,然后在第二环境条件下,纺丝制备第二膜层以及第三膜层,经过干燥、压制处理后得到医用防粘连膜。本发明制备的医用防粘连膜形成水合润层,实现在不载药的情况下,减少术后粘连发生的概率,进而促进结缔组织或骨组织再生,且防粘连率高。(The invention provides a preparation method of a bionic medical anti-adhesion membrane, which comprises the steps of adding PMPC and PCL into a solvent at room temperature, and stirring to prepare a spinning solution; loading the spinning solution into an injector, using an aluminum foil as a receiver, adjusting the distance between a spinning device and the receiver to be 16-20cm, applying voltage to be 10-30kv, spinning to prepare a first film layer under a first environmental condition, then spinning to prepare a second film layer and a third film layer under a second environmental condition, and drying and pressing to obtain the medical anti-adhesion film. The medical anti-adhesion membrane prepared by the invention forms a hydrated moist layer, reduces the probability of postoperative adhesion under the condition of no drug loading, further promotes the regeneration of connective tissues or bone tissues, and has high anti-adhesion rate.)

1. A preparation method of a bionic medical anti-adhesion membrane is characterized by comprising the following steps:

adding PMPC and PCL into a solvent at room temperature, and stirring to prepare a spinning solution;

loading the spinning solution into an injector, using an aluminum foil as a receiver, adjusting the distance between a spinning device and the receiver to be 16-20cm, applying voltage to be 10-30kv, spinning under a first environmental condition to prepare a first film layer, then spinning under a second environmental condition to prepare a second film layer and a third film layer, and drying and pressing to obtain the medical anti-adhesion film.

2. The preparation method of the bionic medical anti-adhesion membrane as claimed in claim 1, wherein the PMPC accounts for 1-15% of the spinning solution by mass percentage, and the PMPC has an average molecular weight of 20 kDa.

3. The preparation method of the bionic medical anti-adhesion membrane according to claim 1, wherein the PCL accounts for 10-20% of the spinning solution by mass percent, and has an average molecular weight of 80 kDa.

4. The method for preparing the biomimetic medical anti-adhesion membrane according to claim 1, wherein the solvent is one or both of hexafluoroisopropanol and dichloromethane.

5. The method for preparing the bionic medical anti-adhesion membrane as claimed in claim 1, wherein the stirring speed is 500r/min-8000r/nim and the stirring time is 24 h.

6. The method of claim 1, wherein the first environmental condition has a relative humidity of 40% rh to 80% rh.

7. The method of claim 1, wherein the relative humidity of the second environmental condition is between 25% rh and 38% rh.

8. The method for preparing a biomimetic medical anti-adhesive membrane according to claim 7, wherein the spinning speed is 0.6ml/h and the spinning time is 1h when preparing the first membrane layer.

9. The method of claim 7, wherein the spinning speed is 1.0ml/h for the second and third layers.

10. The method for preparing a biomimetic medical anti-adhesive membrane according to claim 9, wherein the pressure of the pressing treatment is 0.6-0.8MPa, and the time of the pressing treatment is 2-4 min.

Technical Field

The invention relates to the field of medical biology, in particular to a preparation method of a medical anti-adhesion membrane.

Background

The application of the anti-adhesion membrane in surgical operation is more extensive, and the anti-adhesion membrane can effectively prevent postoperative tissue adhesion and effectively reduce the occurrence of problems of secondary trauma and the like. The anti-adhesion membrane generally requires an anti-adhesion function, and has the capabilities of ventilation and nutrient substance permeation. The nanofiber membrane prepared by the electrostatic spinning technology has the excellent characteristics of large surface area, high porosity, nano level, good mechanical strength and the like, and also has excellent biocompatibility, biodegradability, tissue guiding function and the like. At present, the main anti-adhesion membrane is mainly a nanofiber membrane taking chitosan or collagen and the like as a base layer, sodium hyaluronate is loaded, and the membrane has the function of inhibiting tissue adhesion, such as ibuprofen, mitomycin and other medicines, but the side effect of the medicines can slow down the tissue repair speed and prolong the recovery time, and in addition, under the condition of loading the medicines, the anti-adhesion rate of the anti-adhesion membrane is generally about 60%, so that a lower anti-adhesion effect is shown.

In conclusion, the above problems still remain to be solved in the field of preparing medical anti-adhesion membranes.

Disclosure of Invention

Based on the above, in order to solve the problems that the anti-adhesion membrane slows down tissue repair and has low anti-adhesion rate in the prior art, the invention provides a preparation method of a medical anti-adhesion membrane, and the specific technical scheme is as follows:

a preparation method of a medical anti-adhesion membrane comprises the following steps:

adding PMPC and PCL into a solvent at room temperature, and stirring to prepare a spinning solution;

loading the spinning solution into an injector, using an aluminum foil as a receiver, adjusting the distance between a spinning device and the receiver to be 16-20cm, applying voltage to be 10-30kv, spinning under a first environmental condition to prepare a first film layer, then spinning under a second environmental condition to prepare a second film layer and a third film layer, and drying and pressing to obtain the medical anti-adhesion film.

Preferably, PMPC accounts for 1-15% of the spinning solution in percentage by mass, and PMPC has an average molecular weight of 20 kDa.

Preferably, the PCL accounts for 10-20% of the spinning solution by mass percent, and the PCL has an average molecular weight of 80 kDa.

Preferably, the solvent is one or two of hexafluoroisopropanol and dichloromethane.

Preferably, the stirring speed is 500r/min-8000r/nim, and the stirring time is 24 h.

Preferably, the relative humidity of the first environmental condition is between 40% rh and 80% rh.

Preferably, the relative humidity of the second ambient condition is between 25% rh and 38% rh.

Preferably, the first film layer is prepared at a spinning speed of 0.6ml/h and a spinning time of 1-3 h.

Preferably, the spinning speed for the preparation of the second film layer as well as the third film layer is 1.0 ml/h.

Preferably, the pressure of the pressing treatment is 0.6-0.8MPa, and the time of the pressing treatment is 2-4 min.

The medical anti-adhesion membrane prepared in the scheme has the structure of the first membrane layer, the second membrane layer and the third membrane layer, the first membrane layer prepared under the first spinning condition absorbs water mist in the air which is fixed and orderly arranged under the action of charged radicals, so that the first membrane layer forms a hydrated moistening layer, the possibility of adhering cell surface protein and polypeptide to the surface of the membrane is reduced under the condition of no drug loading, the probability of postoperative adhesion is reduced, and then the regeneration of connective tissue or bone tissue is promoted, and the anti-adhesion rate is effectively improved. In addition, the anti-adhesion membrane prepared by the invention can be combined with other tissue-guided regeneration membranes to form a composite membrane for use, and has wider application space.

Drawings

FIG. 1 is a schematic diagram showing the cell adhesion preventing effect of the biomimetic medical anti-adhesion membrane prepared in the present invention;

fig. 2 is an electron microscopic view of the biomimetic medical anti-adhesion membrane prepared in examples 1-4 of the present invention, wherein, a first is an electron microscopic view of the biomimetic medical anti-adhesion membrane prepared in example 1, a second is an electron microscopic view of the biomimetic medical anti-adhesion membrane prepared in example 2, a third is an electron microscopic view of the biomimetic medical anti-adhesion membrane prepared in example 3, and a fourth is an electron microscopic view of the biomimetic medical anti-adhesion membrane prepared in example 4;

fig. 3 is a schematic view showing the measurement results of the water contact angle of the biomimetic medical anti-adhesion membrane prepared in examples 1-4 according to the present invention, wherein, a first is a schematic view showing the measurement results of the water contact angle of the biomimetic medical anti-adhesion membrane prepared in example 1, a second is a schematic view showing the measurement results of the water contact angle of the biomimetic medical anti-adhesion membrane prepared in example 2, a third is a schematic view showing the measurement results of the water contact angle of the biomimetic medical anti-adhesion membrane prepared in example 3, and a fourth is a schematic view showing the measurement results of the water contact angle of the biomimetic medical anti-adhesion membrane prepared in example 4;

FIG. 4 is a schematic diagram showing results of cell anti-adhesion experiments on the biomimetic medical anti-adhesion membrane prepared in examples 1-4 and a control group, wherein the first diagram is a schematic diagram showing results of cell anti-adhesion experiments on the biomimetic medical anti-adhesion membrane prepared in example 1, the second diagram is a schematic diagram showing results of cell anti-adhesion experiments on the biomimetic medical anti-adhesion membrane prepared in example 2, the third diagram is a schematic diagram showing results of cell anti-adhesion experiments on the biomimetic medical anti-adhesion membrane prepared in example 3, and the fourth diagram is a schematic diagram showing results of cell anti-adhesion experiments on the biomimetic medical anti-adhesion membrane prepared in example 4;

fig. 5 is a schematic diagram of fluorescence characterization of cell anti-adhesion experiments of the biomimetic medical anti-adhesion membrane prepared in example 1-4 and a control group, wherein the first part is a schematic diagram of fluorescence characterization of cell anti-adhesion experiments of the biomimetic medical anti-adhesion membrane prepared in example 1, the second part is a schematic diagram of fluorescence characterization of cell anti-adhesion experiments of the biomimetic medical anti-adhesion membrane prepared in example 2, the third part is a schematic diagram of fluorescence characterization of cell anti-adhesion experiments of the biomimetic medical anti-adhesion membrane prepared in example 3, and the fourth part is a schematic diagram of fluorescence characterization of cell anti-adhesion experiments of the biomimetic medical anti-adhesion membrane prepared in example 4.

Detailed Description

In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail below with reference to embodiments thereof. It should be understood that the detailed description and specific examples, while indicating the scope of the invention, are intended for purposes of illustration only and are not intended to limit the scope of the invention.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used herein in the description of the invention is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used herein, the term "and/or" includes any and all combinations of one or more of the associated listed items.

In the present application, the PMPC is poly 2-methacryloyloxyethyl phosphorylcholine; the PCL is polycaprolactone.

The preparation method of the bionic medical anti-adhesion membrane in one embodiment of the invention comprises the following steps:

adding PMPC and PCL into a solvent at room temperature, and stirring to prepare a spinning solution;

loading the spinning solution into an injector, using an aluminum foil as a receiver, adjusting the distance between a spinning device and the receiver to be 16-20cm, applying voltage to be 10-30kv, spinning under a first environmental condition to prepare a first film layer, then spinning under a second environmental condition to prepare a second film layer and a third film layer, and drying and pressing to obtain the medical anti-adhesion film.

In one embodiment, PMPC comprises 1% to 15% of the spinning solution by mass, and PMPC has an average molecular weight of 20 kDa; preferably: the PMPC accounts for 6% -8% of the spinning solution.

In one embodiment, the PCL accounts for 10% -20% of the spinning solution by mass, and has an average molecular weight of 80 kDa.

In one embodiment, the solvent is one or two of hexafluoroisopropanol and dichloromethane.

In one embodiment, the stirring speed is 500r/min-8000r/nim, and the stirring time is 24 h.

In one embodiment, the first environmental condition has a relative humidity of 40% rh to 80% rh and a temperature of 24 ℃ to 26 ℃.

In one embodiment, the relative humidity of the second ambient condition is between 25% rh and 38% rh.

In one example, the first film layer was prepared at a spinning speed of 0.6ml/h and a spinning time of 1 h.

In one embodiment, the second film layer and the third film layer are prepared at a spinning speed of 1.0 ml/h.

In one embodiment, the pressure of the pressing treatment is 0.6-0.8MPa, and the time of the pressing treatment is 2-4 min.

The surface layer of the joint cartilage of vertebrates is as smooth as an ice surface, a large amount of phosphatidylcholine lipid is enriched in the surface layer, the branched chain of the phosphatidylcholine lipid has the structure of an amphoteric charged group which is respectively a positively charged (N + (CH3)3) group and a negatively charged (PO4-) group, and the two groups are orderly arranged along with the phosphatidylcholine lipid, so that water molecules can form a stable hydrated moist layer on the surface of the bone joint, and the joint cartilage forms a super-smooth surface similar to the ice surface. Therefore, the mechanical bionics is carried out on the surface of the articular cartilage, and the medical anti-adhesion membrane with the ultra-smooth surface is produced by combining the phosphatidylcholine with the electrostatic spinning.

The bionic medical anti-adhesion membrane prepared in the scheme has the structure of the first membrane layer, the second membrane layer and the third membrane layer, the first membrane layer prepared under the first spinning condition absorbs water mist in the air which is fixed and orderly arranged under the action of charged radicals, so that the first membrane layer forms a hydrated wetting layer, the probability of postoperative adhesion is reduced under the condition of no drug loading, then connective tissue or bone tissue regeneration is promoted, and the anti-adhesion rate is effectively improved. In addition, the bionic medical anti-adhesion membrane prepared by the invention can be used with other tissue-guided regeneration membranes to form a composite membrane, and has wider application space.

Embodiments of the present invention will be described in detail below with reference to specific examples.

Example 1:

adding 0.4g of PMPC and 3g of PCL into 20mL of hexafluoroisopropanol at room temperature, and stirring for 24 hours at the speed of 500r/min to obtain a spinning solution;

loading the spinning solution into an injector, using an aluminum foil as a receiver to be flatly paved on a table, adjusting the distance between a spinning device and the receiver to be 18cm, applying voltage to be 20kv, spinning for 1h under the conditions that the relative humidity is 40% rh, the temperature is 26 ℃ and the spinning speed is 0.6ml/h to prepare a first film layer, then spinning for preparing a second film layer and a third film layer under the conditions that the relative humidity is 25% rh, the temperature is 24 ℃ and the spinning speed is 1.0ml/h, placing in an oven to dry for 12h at room temperature, pressing for 3min under the pressure of 0.6MPa, and sterilizing by using ethylene oxide gas after packaging to obtain the bionic medical anti-adhesion film marked as I.

Example 2:

adding 1.2g of PMPC and 3g of PCL into 20mL of hexafluoroisopropanol at room temperature, and stirring for 24 hours at the speed of 1000r/min to obtain a spinning solution;

loading the spinning solution into an injector, using an aluminum foil as a receiver to be flatly paved on a table, adjusting the distance between a spinning device and the receiver to be 18cm, applying voltage to be 20kv, spinning for 1h under the conditions that the relative humidity is 50% rh, the temperature is 24 ℃ and the spinning speed is 0.6ml/h to prepare a first film layer, then spinning for preparing a second film layer and a third film layer under the conditions that the relative humidity is 28% rh, the temperature is 24 ℃ and the spinning speed is 1.0ml/h, placing in an oven to dry for 12h at room temperature, pressing for 3min under the pressure of 0.6MPa, and sterilizing by using ethylene oxide gas after packaging to obtain the bionic medical anti-adhesion film marked as No. two.

Example 3:

adding 1.6g of PMPC and 3g of PCL into 20mL of hexafluoroisopropanol at room temperature, and stirring for 24 hours at 1500r/min to obtain a spinning solution;

loading the spinning solution into an injector, using an aluminum foil as a receiver to be flatly paved on a table, adjusting the distance between a spinning device and the receiver to be 18cm, applying voltage to be 20kv, spinning for 1h under the conditions that the relative humidity is 60% rh, the temperature is 24 ℃ and the spinning speed is 0.6ml/h to prepare a first film layer, then spinning for preparing a second film layer and a third film layer under the conditions that the relative humidity is 25% rh, the temperature is 24 ℃ and the spinning speed is 1.0ml/h, placing in an oven to dry for 12h at room temperature, pressing for 3min under the pressure of 0.6MPa, and sterilizing by using ethylene oxide gas after packaging to obtain the bionic medical anti-adhesion film marked as No. three.

Example 4:

adding 1.6g of PMPC and 2g of PCL into 20mL of dichloromethane at room temperature, and stirring for 24 hours at the speed of 1000r/min to obtain a spinning solution;

loading the spinning solution into an injector, using an aluminum foil as a receiver to be flatly paved on a table, adjusting the distance between a spinning device and the receiver to be 18cm, applying voltage to be 20kv, spinning for 1h under the conditions that the relative humidity is 40% rh, the temperature is 26 ℃ and the spinning speed is 0.6ml/h to prepare a first film layer, then spinning for preparing a second film layer and a third film layer under the conditions that the relative humidity is 25% rh, the temperature is 24 ℃ and the spinning speed is 1.0ml/h, placing in an oven to dry for 12h at room temperature, pressing for 3min under the pressure of 0.6MPa, and sterilizing by using ethylene oxide gas after packaging to obtain the bionic medical anti-adhesion film marked as No. four.

Fig. 1 is a schematic view of the cell adhesion preventing effect of the biomimetic medical anti-adhesion membrane prepared in example 1 of the present invention, and it can be seen from fig. 1 that the biomimetic medical anti-adhesion membrane prepared in the present invention has a hydrated wetting layer, and the charged groups on the fiber surface are orderly arranged, and after absorbing water molecules, an ordered hydrated wetting layer is formed on the surface, so as to achieve an excellent anti-adhesion effect; fig. 2 is an electron microscopic view of the biomimetic medical anti-adhesion membrane prepared in examples 1-4 of the present invention, wherein, a first is an electron microscopic view of the biomimetic medical anti-adhesion membrane prepared in example 1, a second is an electron microscopic view of the biomimetic medical anti-adhesion membrane prepared in example 2, a third is an electron microscopic view of the biomimetic medical anti-adhesion membrane prepared in example 3, and a fourth is an electron microscopic view of the biomimetic medical anti-adhesion membrane prepared in example 4, and as can be seen from the analysis of fig. 2: the bionic medical anti-adhesion membrane prepared by the method has a certain degree of blending, and is beneficial to water absorption; fig. 3 is a schematic view of a measurement result of a water contact angle of the biomimetic medical anti-adhesion membrane prepared in examples 1-4 of the present invention, wherein, a first is a schematic view of a measurement result of a water contact angle of the biomimetic medical anti-adhesion membrane prepared in example 1, a second is a schematic view of a measurement result of a water contact angle of the biomimetic medical anti-adhesion membrane prepared in example 2, a third is a schematic view of a measurement result of a water contact angle of the biomimetic medical anti-adhesion membrane prepared in example 3, and a fourth is a schematic view of a measurement result of a water contact angle of the biomimetic medical anti-adhesion membrane prepared in example 4, and it can be seen from an analysis of fig. 3: the bionic medical anti-adhesion membrane prepared by the invention is a hydrophobic material, has an excellent waterproof effect and is beneficial to promoting the self-repair of tissues.

In addition, the bionic medical anti-adhesion membranes prepared in examples 1 to 4 were subjected to a cell adhesion resistance test by the following method: mouse embryonic cells NIH/3T3 cells were used for the experiments. Different groups of patches were cut to size and placed in culture plates, and then sterilized with UV for 24 h. After inoculation of the cell suspension, at 37 ℃ and 5% CO₂The cells were cultured under ambient conditions until characterized and the number of cell proliferations was measured based on the cell counting kit method. After 1 day, 3 days and 7 days of culture, refreshing with 100. mu.L of CCK-8 test solution and incubating together for 2 hours, then reading the absorbance of the final solution at 450nm by a microplate reader, and obtaining the cell proliferation amount according to the comparison of the absorbance of standard cells. Also, after 1 day, 3 days and 7 days of culture, each well was mixed-stained with 500. mu.L of 2mM calcein and 10mM of homodimeric ethylamine-1 (EthD-1) for 30min, followed by staining with 1mg/ml of DAPI for five minutes after completion and finally visual recording with a confocal laser scanning microscope. The control group was blank. The results are shown in fig. 4 and 5, wherein fig. 4 is a schematic diagram of the results of the cell anti-adhesion experiment of the biomimetic medical anti-adhesion membrane prepared in examples 1-4 of the present invention and the control group; FIG. 5 is a schematic fluorescence characterization diagram of the cell anti-adhesion experiment for the bionic medical anti-adhesion membrane prepared in the embodiments 1-4 of the present invention and the control group, and is shown in FIG. 4 and the figure5, analysis shows that: cell number and dead and live cell distribution fluorescence images are counted in 1 day, 3 days and 7 days of culture, and it can be obviously seen that the enhancement of the cell adhesion resistance of the bionic medical anti-adhesion membrane prepared by the invention compared with blank groups and control groups leads cell proliferation to be slower and slower, and the bionic medical anti-adhesion membrane has an anti-adhesion effect.

The technical features of the embodiments described above may be arbitrarily combined, and for the sake of brevity, all possible combinations of the technical features in the embodiments described above are not described, but should be considered as being within the scope of the present specification as long as there is no contradiction between the combinations of the technical features.

The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.